Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$232.23−4.75 (-2.00%)
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Biotechnology — Adjusted EBITDA: $3,016M in FY2025, up 11.7% from a year earlier.
Latest, FY2025
3,016
Period ended Dec 31, 2025
Change on a year earlier
+11.7%
2,699 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Danaher IR — nongaap_2025Q4 ↗
Reported in Danaher Non-GAAP Reconciliations & Supplemental Data (8-K / IR PDF).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biotechnology — Adjusted EBITDA ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,016 | +11.7% | Danaher IR — nongaap_2025Q4 ↗ |
| FY2024 | Dec 31, 2024 | 2,699 | -9.7% | Danaher IR — nongaap_2025Q4 ↗ |
| FY2023 | Dec 31, 2023 | 2,989 | -25.7% | Danaher IR — nongaap_2024Q4 ↗ |
| FY2022 | Dec 31, 2022 | 4,024 | -3.7% | Danaher IR — nongaap_ex_veralto ↗ |
| FY2021 | Dec 31, 2021 | 4,179 | – | Danaher IR — nongaap_ex_veralto ↗ |
Cite this data
StockData. (2026). Danaher Biotechnology — Adjusted EBITDA ($M), annual FY2021–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/adj-ebitda-biotech
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.